Interleukin 13 and the β-adrenergic blockade theory of asthma revisited 40 years later

Robert G. Townley

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Background: β2-Adrenergic agonists are the most potent agents clinically used in inhibiting and preventing the immediate response to bronchoconstricting agents and in inhibiting mast cell mediator release. This raises the possibility that an abnormality in β-adrenergic receptor function or circulating catecholamine levels could contribute to airway hyperresponsiveness. Objective: To link interleukin 13 (IL-13) to the pathogenesis of asthma. Methods: Almost 4 decades ago, Andor Szentivanyi published a β-adrenergic theory of atopic abnormality in bronchial asthma. He proposed 9 characteristics to define bronchial asthma. Because he published these 9 tenets of the β-adrenergic blockade theory of asthma in 1968, it is appropriate and important to evaluate their relevance in light of advances in pharmacology, inflammation, and immunology. Results: We describe the effects of the allergic reaction on β-adrenergic responses and airway responsiveness. Both IL-1β and tumor necrosis factor α have been detected in increased amounts in bronchial lavage fluids in allergic airway inflammation. Both IL-13 and the proinflammatory cytokines IL-1β and tumor necrosis factor α have been demonstrated in airway smooth muscle to cause a decreased relaxation response to β-adrenergic agonist. However, IL-13 has been shown to be necessary and sufficient to produce the characteristics of asthma. Conclusion: The decreased adrenergic bronchodilator activity and associated hypersensitivity to mediators put forth by Szentivanyi can be elicited with IL-13 and support its role in the pathogenesis of asthma.

Original languageEnglish
Pages (from-to)215-224
Number of pages10
JournalAnnals of Allergy, Asthma and Immunology
Volume99
Issue number3
StatePublished - Sep 2007

Fingerprint

Interleukin-13
Adrenergic Agents
Asthma
Adrenergic Agonists
Interleukin-1
Hypersensitivity
Tumor Necrosis Factor-alpha
Inflammation
Bronchodilator Agents
Bronchoalveolar Lavage Fluid
Allergy and Immunology
Mast Cells
Adrenergic Receptors
Catecholamines
Smooth Muscle
Pharmacology
Cytokines

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Interleukin 13 and the β-adrenergic blockade theory of asthma revisited 40 years later. / Townley, Robert G.

In: Annals of Allergy, Asthma and Immunology, Vol. 99, No. 3, 09.2007, p. 215-224.

Research output: Contribution to journalReview article

@article{4b8f4d24d3fc4c4db0d959008275d99c,
title = "Interleukin 13 and the β-adrenergic blockade theory of asthma revisited 40 years later",
abstract = "Background: β2-Adrenergic agonists are the most potent agents clinically used in inhibiting and preventing the immediate response to bronchoconstricting agents and in inhibiting mast cell mediator release. This raises the possibility that an abnormality in β-adrenergic receptor function or circulating catecholamine levels could contribute to airway hyperresponsiveness. Objective: To link interleukin 13 (IL-13) to the pathogenesis of asthma. Methods: Almost 4 decades ago, Andor Szentivanyi published a β-adrenergic theory of atopic abnormality in bronchial asthma. He proposed 9 characteristics to define bronchial asthma. Because he published these 9 tenets of the β-adrenergic blockade theory of asthma in 1968, it is appropriate and important to evaluate their relevance in light of advances in pharmacology, inflammation, and immunology. Results: We describe the effects of the allergic reaction on β-adrenergic responses and airway responsiveness. Both IL-1β and tumor necrosis factor α have been detected in increased amounts in bronchial lavage fluids in allergic airway inflammation. Both IL-13 and the proinflammatory cytokines IL-1β and tumor necrosis factor α have been demonstrated in airway smooth muscle to cause a decreased relaxation response to β-adrenergic agonist. However, IL-13 has been shown to be necessary and sufficient to produce the characteristics of asthma. Conclusion: The decreased adrenergic bronchodilator activity and associated hypersensitivity to mediators put forth by Szentivanyi can be elicited with IL-13 and support its role in the pathogenesis of asthma.",
author = "Townley, {Robert G.}",
year = "2007",
month = "9",
language = "English",
volume = "99",
pages = "215--224",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "3",

}

TY - JOUR

T1 - Interleukin 13 and the β-adrenergic blockade theory of asthma revisited 40 years later

AU - Townley, Robert G.

PY - 2007/9

Y1 - 2007/9

N2 - Background: β2-Adrenergic agonists are the most potent agents clinically used in inhibiting and preventing the immediate response to bronchoconstricting agents and in inhibiting mast cell mediator release. This raises the possibility that an abnormality in β-adrenergic receptor function or circulating catecholamine levels could contribute to airway hyperresponsiveness. Objective: To link interleukin 13 (IL-13) to the pathogenesis of asthma. Methods: Almost 4 decades ago, Andor Szentivanyi published a β-adrenergic theory of atopic abnormality in bronchial asthma. He proposed 9 characteristics to define bronchial asthma. Because he published these 9 tenets of the β-adrenergic blockade theory of asthma in 1968, it is appropriate and important to evaluate their relevance in light of advances in pharmacology, inflammation, and immunology. Results: We describe the effects of the allergic reaction on β-adrenergic responses and airway responsiveness. Both IL-1β and tumor necrosis factor α have been detected in increased amounts in bronchial lavage fluids in allergic airway inflammation. Both IL-13 and the proinflammatory cytokines IL-1β and tumor necrosis factor α have been demonstrated in airway smooth muscle to cause a decreased relaxation response to β-adrenergic agonist. However, IL-13 has been shown to be necessary and sufficient to produce the characteristics of asthma. Conclusion: The decreased adrenergic bronchodilator activity and associated hypersensitivity to mediators put forth by Szentivanyi can be elicited with IL-13 and support its role in the pathogenesis of asthma.

AB - Background: β2-Adrenergic agonists are the most potent agents clinically used in inhibiting and preventing the immediate response to bronchoconstricting agents and in inhibiting mast cell mediator release. This raises the possibility that an abnormality in β-adrenergic receptor function or circulating catecholamine levels could contribute to airway hyperresponsiveness. Objective: To link interleukin 13 (IL-13) to the pathogenesis of asthma. Methods: Almost 4 decades ago, Andor Szentivanyi published a β-adrenergic theory of atopic abnormality in bronchial asthma. He proposed 9 characteristics to define bronchial asthma. Because he published these 9 tenets of the β-adrenergic blockade theory of asthma in 1968, it is appropriate and important to evaluate their relevance in light of advances in pharmacology, inflammation, and immunology. Results: We describe the effects of the allergic reaction on β-adrenergic responses and airway responsiveness. Both IL-1β and tumor necrosis factor α have been detected in increased amounts in bronchial lavage fluids in allergic airway inflammation. Both IL-13 and the proinflammatory cytokines IL-1β and tumor necrosis factor α have been demonstrated in airway smooth muscle to cause a decreased relaxation response to β-adrenergic agonist. However, IL-13 has been shown to be necessary and sufficient to produce the characteristics of asthma. Conclusion: The decreased adrenergic bronchodilator activity and associated hypersensitivity to mediators put forth by Szentivanyi can be elicited with IL-13 and support its role in the pathogenesis of asthma.

UR - http://www.scopus.com/inward/record.url?scp=34548688420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548688420&partnerID=8YFLogxK

M3 - Review article

VL - 99

SP - 215

EP - 224

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 3

ER -